Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health
Obesity is a major risk factor for many chronic conditions like type 2 diabetes and cardiovascular diseases
Providers, too, are looking beyond BMI to better manage comorbidities such as diabetes and cardiovascular risks
.png)
This double-blind, placebo-controlled trial enrolled 9,901 patients and demonstrated that dulaglutide 1.5 mg significantly reduced MACE by 12% (HR 0.88, 95% CI 0.790.99, p=0.026)
US$ 28.37
US$ 27.18
US$ 28.82
US$ 21.33
:max_bytes(150000):strip_icc()/GettyImages-2169095535-f8d8276415dd4300a867a1f8b7de098f.jpg)
